Influence of ketoconazole on the fecal and urinary disposition of docetaxel

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 4, 2007, Pages 569-579

  Engels, Frederike K ^a   Loos, Walter J ^a   Mathot, Ron A A ^a   Van Schaik, Ron H N ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

3H radiolabeled docetaxel; Clinical trial; Docetaxel; Drug interaction; Fecal disposition; Ketoconazole; Mass balance; Urinary disposition

Indexed keywords

DOCETAXEL; KETOCONAZOLE; PANTOPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG MEGADOSE; DRUG POTENTIATION; DRUG URINE LEVEL; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY;

ADMINISTRATION, ORAL; ADULT; AGED; CYTOCHROME P-450 ENZYME SYSTEM; FECES; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; TAXOIDS; TRITIUM;

EID: 34447527592     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0412-5     Document Type: Article

References (45)

1. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
2. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58-65
3. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV (1998) Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391-401
4. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671
5. Ringel I, Horwitz SB (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291
6. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K (1999) Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 90:1380-1386
7. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81
8. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598-2603
9. van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, Bol CJ, de Vries R, Palmer PA, Verweij J (2002) Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 38:1090-1099
10. Bruno R, Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 17:305-313
11. Gaillard C, Monsarrat B, Vuilhorgne M, Royer I, Monegier B, Sable S, Guenard C, Gires P, Archimbaud Y, Wright M, Sanderink GJ (1994) Docetaxel (Taxotere) metabolism in the rat in vivo and in vitro. Proc Am Assoc Cancer Res 35:2553a
12. Marlard M, Gaillard C, Sanderink GJ, Roberts S, Joannou P, Facchini V, Chapelle P, Frydman A (1993) Kinetics, distribution, metabolism and excretion of radiolabelled Taxotere (14C-RP56976) in mice and dogs. Proc Am Assoc Cancer Res 34:2343a
13. Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C, Beijnen JH (1996) Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24:655-658
14. Bardelmeijer HA, Roelofs AB, Hillebrand MJ, Beijnen JH, Schellens JH, van Tellingen O (2005) Metabolism of docetaxel in mice. Cancer Chemother Pharmacol 56:299-306
15. 14 radiolabelled Taxotere (TXT) (RP56976, NSC628503) in cancer patients. Proc Am Assoc Cancer Res 34:2221a
16. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179
17. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948
18. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660
19. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75:448-454
20. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J (2006a) Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 5:833-839
21. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294
22. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388
23. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10:8341-8350
24. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr., Bhat K, Kim RB, Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606
25. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA (2005) Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302-309
26. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
27. Gibbs MA, Thummel KE, Shen DD, Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187
28. Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azema J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roche H (2004) Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 54:265-272
29. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Schuetz E, Lim R, Lim HL, Ong AB, Lee HS (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
30. Nizoral prescribing information. http://www.janssen.com
31. Figg WD, Liu Y, Acharya MR, Gulley J, Arlen PM, Lewis M, Parnes HL, Chen CC, Jones E, Dahut W (2003) A phase I trial of high dose ketoconazole plus weekly docetaxel in metastatic androgen independent prostate cancer. Proc Am Soc Clin Oncol 22:1731a
32. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A (1997) Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 693:437-441
33. Engels FK, Buijs D, Loos WJ, Verweij J, Bakker WH, Krenning EP (2006b) Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method. Anticancer Drugs 17:63-67
34. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J (2000) CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 46:1834-1836
35. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J (2001) The CYP3A4*3 allele: is it really rare? Clin Chem 47:1104-1106
36. Daneshmend TK, Warnock DW (1998) Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 14:13-34
37. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68:1889-1902
38. Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R (2005) Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 11:6972-6979
39. Tham LS, Goh BC, Wang LZ, Yong WP, Wong CI, Lee SC, Soo R, Sukri N, Lee HS (2006) Ketoconazole inhibition of CYP3A activity made midazolam but not docetaxel pharmaockinetics more predictable [abstract # PI-62] Proc Am Soc Clin Pharmacol Ther. Clin Pharmacol Ther 76:P23
40. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196
41. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153-172
42. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 46:160-165
43. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738
44. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71:297-303
45. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H (2002) Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13:1847-1854